Phase I study of VGX-100, an anti-VEGF-C monoclonal antibody, with or without bevacizumab, in patients (pts) with advanced solid tumors.
Gerald Steven Falchook
Research Funding - Circadian
Jayesh Desai
Consultant or Advisory Role - Vegenics
Ian M. Leitch
Employment or Leadership Position - Vegenics
Stock Ownership - Circadian
Jonathan Wade Goldman
No relevant relationships to disclose
Jennifer J. Wheler
No relevant relationships to disclose
Siqing Fu
No relevant relationships to disclose
Razelle Kurzrock
No relevant relationships to disclose
Megan Baldwin
Employment or Leadership Position - Vegenics
Stock Ownership - Circadian
Lee S. Rosen
Research Funding - Vegenics